ReveraGen BioPharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.reveragen.com
Clinical Trials
22
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT05166109
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇮🇹Azienda Ospedale Universita Padova, Padova, Italy
Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis
- Conditions
- Pediatric Ulcerative Colitis
- Interventions
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Registration Number
- NCT04348890
A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT03439670
- Locations
- 🇺🇸
University of California Davis, Davis, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT03038399
- Locations
- 🇺🇸
University of California Davis, Davis, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Nemours Children's Hospital, Orlando, Florida, United States
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02760264
- Locations
- 🇺🇸
University of California Davis, Davis, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Nemours Children's Hospital, Orlando, Florida, United States
- Prev
- 1
- 2
- Next